However, further studies are needed to determine the toxicity and tolerability of TLR4 inhibitors in humans and to confirm whether TAK-242 can be effective in preventing HCC in humans with NASH [97]. This evidence concerns the gene TLR4 and metabolic dysfunction-associated steatohepatitis.